OBJECTIVES: To determine drug requirement for treatment advanced Hodgkin's disease. METHODS: Drug requirement was calculated on the basis of data about recommended treatment schemes of Hodgkin's disease (HD), amount of treatment courses for one case of HD and average body surface area of patients with HD. Average body surface area calculated on the basis of medical documentation of 182 HD patients were treated in HSC RAMS. Drug requirement in specified region or public health institution was calculated based on frequency of advanced HD in these region or institution (in our case - HSC RAMS). RESULTS: HD treatment schemes BEACOPP-14 is pharmacoeconomic dominate alternative (Tolkushin A.G. et al. 2006). Average body surface area amount to 1.77±0.037 m2. Amount of treatment courses for one case of HD were 6. Average drug requirement were 6.90 g or 69 vials in 100 mg of Cyclophosphamide, 3.98 g or 8 vials in 500 mg of Dacarbazine, 266 mg or 5 vials in 50 mg of Doxorubicin, 3.19 g or 32 vials in 100 mg of Etoposide, 106 mg or 7 vials in 15 mg of Bleomycin, 15 mg or 15 vials in 1 mg of Vincristine and 5.95 g or 1.2 thousand tablets in 5 mg of Prednisolone. Average number of advanced HD patients in HIT department of HSC RAMS were 20 patients per year. Average annual drug requirement in HIT department of HSC RAMS were 138, 159, 106, 637, 142, 297 vials and 23.7 thousand tablets of Cyclophosphamide, Dacarbazine, Doxorubicin, Etoposide, Bleomycin, Vincristine and Prednisolone, respectively. CONCLUSION: The drug requirement for one case of advanced Hodgkin's disease and average annual drug requirement in HSC RAMS were determined. If one know average number of Hodgkin's disease patients it is possible to determine amount of drug.